Sugi Predict

Sugi Predict / Compounds / SCHEMBL1876314

SCHEMBL1876314

SCHEMBL1876314

NC(=O)c1[nH]c2cnccc2c1-c1ccc(NC(=O)Nc2ccc(F)c(C(F)(F)F)c2)cc1

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ MAP2 P11137 1/20 0.53
▸ RIPK1 Q13546 3/20 0.52
▸ BLM P54132 1/20 0.48
▸ WRN Q14191 1/20 0.48
▸ KDR P35968 9/20 0.47
▸ FLT3 P36888 4/20 0.47
▸ CSF1R P07333 2/20 0.47
▸ FLT1 P17948 2/20 0.47
▸ FLT4 P35916 2/20 0.47
▸ RET P07949 1/20 0.47
▸ FGFR1 P11362 1/20 0.47
▸ FRK P42685 1/20 0.47
▸ CAMK2B Q13554 1/20 0.47
▸ CAMK2D Q13557 1/20 0.47
▸ NTRK3 Q16288 1/20 0.47
▸ HIPK4 Q8NE63 1/20 0.47
▸ AURKB Q96GD4 1/20 0.47
▸ CDK8 P49336 2/20 0.46
▸ KIT P10721 3/20 0.45
▸ NTRK1 P04629 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1880281 0.90 MAP2 (0.53) MAP2RIPK1BLMKDRFLT3
SCHEMBL1874297 0.90 MAP2 (0.53) MAP2RIPK1BLMKDRFLT1
SCHEMBL1880887 0.87 MEN1 (0.56) MAP2KDRFLT3KITHPSE
SCHEMBL13761322 0.87 KDR (0.54) MAP2RIPK1KDRFLT3CSF1R
SCHEMBL1878506 0.86 KDR (0.56) MAP2RIPK1KDRFLT3CSF1R
SCHEMBL1876616 0.86 MAP2 (0.60) MAP2KDRFLT3FGFR1HPSE
Trifluoroacetic Acid SCHEMBL1876323 0.86 MAP2 (0.53) MAP2KDRFLT3KITIDH2
SCHEMBL1880392 0.85 MAP2 (0.63) MAP2BLMKDRFLT3CDK8
SCHEMBL1883816 0.85 MAP2 (0.59) MAP2RIPK1KDRFLT3CSF1R
SCHEMBL1878205 0.85 KDR (0.58) MAP2RIPK1KDRFLT3CSF1R

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7947706-B2 Anticancer agents; modulate kinases such as KDR (Kinase insert Domain Receptor and Tie-2 (TEK) , a member of the tyrosine kinase receptor family; 3-{4-[3-(2-methoxyphenyl)ureido]phenyl}-1H-pyrrolo[2,3-b]pyridine-2-carboxamide for example SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) 2011-05-24 — — US claimed
EP-1877409-B1 SUBSTITUTED PYRROLO-PYRIDINES, COMPOSITION CONTAINING THEM, METHOD FOR THEIR PRODUCING AND USE THEREOF AVENTIS PHARMA SA (FR) 2009-06-17 — — EP claimed
US-20080139606-A1 Substituted Pyrrolopyridines, Compositions Containing Them, Manufacturing Process Therefor and Use Thereof AVENTIS PHARMA S.A. (FR) 2008-06-12 — — US claimed
EP-1877409-A2 SUBSTITUTED PYRROLO-PYRIDINES, COMPOSITION CONTAINING THEM, METHOD FOR THEIR PRODUCING AND USE THEREOF Aventis Pharma S.A. (FR) 2008-01-16 — — EP claimed
WO-2006114520-A2 SUBSTITUTED PYRROLO-PYRIDINES, COMPOSITION CONTAINING THEM, METHOD FOR THEIR PRODUCING AND USE THEREOF AVENTIS PHARMA S.A. (FR) 2006-11-02 — — WO claimed
US-7947706-B2 Anticancer agents; modulate kinases such as KDR (Kinase insert Domain Receptor and Tie-2 (TEK) , a member of the tyrosine kinase receptor family; 3-{4-[3-(2-methoxyphenyl)ureido]phenyl}-1H-pyrrolo[2,3-b]pyridine-2-carboxamide for example SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) 2011-05-24 — — US disclosed
US-7947706-B2 Anticancer agents; modulate kinases such as KDR (Kinase insert Domain Receptor and Tie-2 (TEK) , a member of the tyrosine kinase receptor family; 3-{4-[3-(2-methoxyphenyl)ureido]phenyl}-1H-pyrrolo[2,3-b]pyridine-2-carboxamide for example SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) 2011-05-24 — — US disclosed
US-7947706-B2 Anticancer agents; modulate kinases such as KDR (Kinase insert Domain Receptor and Tie-2 (TEK) , a member of the tyrosine kinase receptor family; 3-{4-[3-(2-methoxyphenyl)ureido]phenyl}-1H-pyrrolo[2,3-b]pyridine-2-carboxamide for example SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) 2011-05-24 — — US disclosed
EP-1877409-B1 SUBSTITUTED PYRROLO-PYRIDINES, COMPOSITION CONTAINING THEM, METHOD FOR THEIR PRODUCING AND USE THEREOF AVENTIS PHARMA SA (FR) 2009-06-17 — — EP disclosed
US-20080139606-A1 Substituted Pyrrolopyridines, Compositions Containing Them, Manufacturing Process Therefor and Use Thereof AVENTIS PHARMA S.A. (FR) 2008-06-12 — — US disclosed
US-20080139606-A1 Substituted Pyrrolopyridines, Compositions Containing Them, Manufacturing Process Therefor and Use Thereof AVENTIS PHARMA S.A. (FR) 2008-06-12 — — US disclosed
US-20080139606-A1 Substituted Pyrrolopyridines, Compositions Containing Them, Manufacturing Process Therefor and Use Thereof AVENTIS PHARMA S.A. (FR) 2008-06-12 — — US disclosed
EP-1877409-A2 SUBSTITUTED PYRROLO-PYRIDINES, COMPOSITION CONTAINING THEM, METHOD FOR THEIR PRODUCING AND USE THEREOF Aventis Pharma S.A. (FR) 2008-01-16 — — EP disclosed
WO-2006114520-A2 SUBSTITUTED PYRROLO-PYRIDINES, COMPOSITION CONTAINING THEM, METHOD FOR THEIR PRODUCING AND USE THEREOF AVENTIS PHARMA S.A. (FR) 2006-11-02 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080139606-A1 Substituted Pyrrolopyridines, Compositions Containing Them, Manufacturing Process Therefor and Use Thereof WEE1, CNKSR1, WEE2 MAP2 1477/4885RIPK1 3097/4885BLM 3291/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.